Characteristics of a Swedish Patient Registry and Its Application On Unmet Needs Analysis Dr. Dan Mellström 1, Arun Krishna 2, Zhyi Li 3, Chun-Po Steve.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance ABOUT THIS PRESENTATION:
Advertisements

Osteoporosis 9 th January 2013 Dr Julian Tomkinson.
A progressive bone disease characterized by decrease bone mass decreased bone density increased fracture risk Dr Gaurav Rathore MS Ortho, MCh Ortho, FRCS.
The FRAX tool for Osteoporosis Should all GP’s be calculating the Frax score prior to treatment Dr Sanjeev Patel Consultant Physician & Senior Lecturer.
Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist.
Chapter 66 Chapter 66 Clinical Use of Bone Densitometry Copyright © 2013 Elsevier Inc. All rights reserved.
WHO Osteoporosis Definition (1996)
* Or unknown (n=8) Inbal Goldshtein 1, Julie Chandler 2, Varda Shalev 1,3, Sofia Ish –Shalom 4, Allison Martin Nguyen 2, Vanessa Rouach 5, Gabriel Chodick.
Prescribing patterns of anti-osteoporotic medications in patients pre and post discharge from a large teaching hospital for fragility type fractures between.
Osteoporosis Lucy Cowdrey 4 th November What is it?
OSC Recommendations for Bone Mineral Density Reporting Slides prepared by Kerry Siminoski, MD, FRCPC William Leslie, M.Sc., MD,
Osteoporosis Dr. Lauren Phillips Sugar Land Women’s Health.
Bone Health and Osteoporosis
Osteoporosis UBC Internal Medicine Program Dr. Mark Fok Dr. Maria Ashley.
Investigations of Osteoporosis By Jeeves. DEXA/DXA (Dual Energy X-ray Absorptionmetry) This is the gold standard in Osteoporosis diagnosis. Reported as.
Chapter 9 Skeletal health. Chapter overview Introduction Biology of bone Osteoporosis: definition, prevalence and consequences Physical activity and bone.
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
OSTEOPOROSIS 06/25/12 José L. González, PGY3. Definition  Reduction in bone strength  increase risk of fx  T-score: < -2.5 SDs  T-score: 30 yo, matched.
Beyond 5 years Francis F. Lopez, MD Medical Oncology.
Osteoporosis Awareness and Prevention Lunch n Learn Series May 2007.
Osteoporosis Dr. Faik Altıntaş Yeditepe Üniversitesi Tıp Fakültesi
“Known knowns, known unknowns, unknown unknowns….. Ronald Dumsfeld Senior Lecturer in Metabolic Bone Diseases.
Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.
Pattern of Diabetes Emergencies among adult Yemeni Diabetic Patients Dr. Zayed Atef Faculty of Medicine Sana’a University.
A High Prevalence of Vitamin D Inadequacy in a Minimal Trauma Fracture Population A High Prevalence of Vitamin D Inadequacy in a Minimal Trauma Fracture.
Osteoporosis Management: Clinical scenario
UNDERTREATMENT AMONG WOMEN DIAGNOSED WITH OSTEOPOROSIS IN GERMANY Ankita Modi 1, Chun-Po Steve Fan 2, Shuvayu Sen 1 1 Global Health Outcomes, Merck & Company,
Chief Investigator: Dr Lee Shepstone School of Medicine, Health Policy and Practice Collaborating universities:- Birmingham Bristol Manchester Sheffield.
Healthcare Consequences Associated With Non-Compliance in a Managed Care Population Ethel S. Siris, M.D. 1, Ankita Modi, Ph.D. 2, Jackson Tang, M.Sc. 3,
EQ-5D AND QUALITY OF LIFE OF OSTEOPOROSIS AT-RISK PATIENTS IN A SWEDISH OSTEOPOROSIS PATIENT REGISTRY Arun Krishna 1, Dan Mellström 2, Zhiyi Li 3, Chun-Po.
Fracture risk assessment
Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.
Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :
By hamidreza soltanian  Osteoporosis is a Greek word meaning porous bone.  While osteoporosis is mostly seen in women (80 %), it can occur.
1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.
AFF: Bone Density and Structure with BP Use Based on Poster FR0030 “Bone Density and Structure of Patients on Bisphosphonates with Atypical Femur Fractures”
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Aging Q3 ACOVE #9 Osteoporosis Jay Brzezinski, MD Medical University of South Carolina 2011.
Osteoporosis By:Miya Johansen, Chelsey Garner, and Javi Fuentes.
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
Osteoporosis: Measuring the Problem
Osteoporosis Dr Ramin Rafiei Alzahra Hospital Rheumatology Department.
Five-year incident fracture risk assessed by quantitative multisite ultrasound: the Canadian Multicentre Osteoporosis Study. W. P. Olszynski 1, J. P. Brown.
Prediction of Hip Fracture in Elderly Men and Women by Fall-related Factors ND Nguyen, C Pongchaiyakul, JR Center, JA Eisman, TV Nguyen Bone and Mineral.
Prevention and Treatment of Osteoporosis
Re-fracture risk in older patients prescribed bisphosphonates Chiara Sorge Rome, 15th October 2012.
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
Aasis Unnanuntana, MD, MSc Case Discussion: Bone Forming Drug Associate Professor in Orthopaedic Surgery Department of Orthopaedic Surgery, Siriraj Hospital,
Osteodensitometry, Bone Biomechanics and Fracture Risk João Costa, Rui Miranda, Rui Pinto “Normal” Bone Introduction The bone formation takes place in.
Chapter 47 Assessing Fracture Risk: Who Should Be Screened? © American Society for Bone and Mineral Research Contributed by John Schousboe, Brent Taylor,
Osteopenia and Osteoporosis Bradley K. Harrison, MD.
NICE, FRAX & NOGG VTS meeting Jonathan Day 7 th April 2010.
Moji Saberin-Williams, M.D. Paoli Hospital Obstetrician/Gynecologist
Count Age (y) Height (cm) Weight (kg) BMI (kg/m 2 ) (DOI) (mo) Tetra/Para Male/Female N=15 35±15 174± ± ±5.4 54±71 9 / 6 12 / 3 Range 20 –
Dual Energy X-ray Absorptiometry (DXA) Services in Ireland – how do we fare? M O’Connor (Dept of Public Health, Dr Steevens’ Hospital, Dublin 8) S Van.
Consequences Of Non-Compliance To Osteoporosis Medication Among Osteoporotic Women Ankita Modi, Ph.D, M.D. 1, Jackson Tang, M.Sc. 2, Shuvayu Sen, Ph.D.
OSTEOPOROSIS Dr Annie Cooper Consultant Rheumatologist Royal Hampshire County Hospital Winchester.
R1 김형오 / Prof. 김덕윤 1.  Osteoporosis  Asian region is considered to be on the verge of an emerging osteoporosis epidemic  50% of the world’s osteoporotic.
Bone Densitometry.
Patient 65 years old retired teacher with severe back pain
Post Menopausal Osteoporosis
Osteoporosis Diagnosis 9/21/2018 OSTEOPOROSIS.
Osteoporosis Definition
Ronald D. Emkey, MD, Mark Ettinger, MD 
Rhematoid Rthritis Respiratory disorders
(Relates to Chapter 64, “Focous on osteoperosis ,” in the textbook)
Reporting the Results of DXA Scan
Consultant Rheumatologist Imperial College Healthcare
Presentation transcript:

Characteristics of a Swedish Patient Registry and Its Application On Unmet Needs Analysis Dr. Dan Mellström 1, Arun Krishna 2, Zhyi Li 3, Chun-Po Steve Fan 3, Stina Salomonsson 2, Dr. Ewa Waern 1 1 Centre for Bone and Arthritis Research at Sahlgrenska Academy, University of Gothenburg, Sweden; 2 Merck & Co., Inc.; 3 AsclepiusJT LLC Characteristics of a Swedish Patient Registry and Its Application On Unmet Needs Analysis Dr. Dan Mellström 1, Arun Krishna 2, Zhyi Li 3, Chun-Po Steve Fan 3, Stina Salomonsson 2, Dr. Ewa Waern 1 1 Centre for Bone and Arthritis Research at Sahlgrenska Academy, University of Gothenburg, Sweden; 2 Merck & Co., Inc.; 3 AsclepiusJT LLC Objective To provide an overview of a Swedish osteoporosis patient registry - describe characteristics, treatment patterns and quality of life among subjects enrolled in the registry. To utilize this registry for analyzing unmet needs of osteoporosis – those remaining at a high risk of fractures despite benefit from prior treatment. Background Establishment of registry The registry was established at the osteoporosis clinic at Sahlgrenska University hospital, Göteborg, in the West region of Sweden encompassing about 2 million inhabitants. Patients were referred to enter the registry by GPs, gynecologists, etc for dual- energy X-ray absorptiometry (DXA) for bone mineral density (BMD) assessment and diagnosis of osteoporosis (OP) A follow-up visit would be scheduled in every other year if low BMD and/or OP diagnosis was indicated in the prior visit. If the follow-up visit was cancelled, then the patient would no longer be followed. Data availability:1991 to Information collected at each visit Clinical assessments: o Patient’s info (age, gender, height, and weight) o BMD scan results (lumbar/spine, total hip and total body) o T-score (lumbar/spine, total hip and total body), o Diagnosis (Normal, Osteopenia, established OP, OP, Male OP) o Type of referrals (GPs, gynecologists, orthopedists, rheumatologists, or other) o Comorbid conditions (secondary OP, rheumatoid arthritis etc) Self-reported outcomes (through self-completing questionnaire): o Fractures after age 40 o Patient characteristics (smoking status, alcohol, back pain, family history of fractures, history of falls) o Current and previous use of OP treatment and glucocorticoids o History of chronic diseases o Quality of life using EQ-5D (collected after 2004) Presented at The American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting, Baltimore, MD, October 4 – 7, 2013 Plenary Poster FR 0404 / Poster session 1 SA 0404 Advantage of the Swedish Registry Contains critical variables of interest Fracture infoBMD (T-score)OP treatment OP diagnosisEQ-5D Longitudinal data over time ~4,000 (45%) patients with 2 or more visits Collection Period: Patient entered registry 2004 Started collecting EQ-5D in questionnaire Year 0 1) Received BMD test 2) Diagnosed for OP 3) Completed questionnaire Low BMD and/or OP diagnosis 1) Received BMD test 2) Diagnosed for OP 3) Completed questionnaire Continued follow- up every 2 years if Low BMD and/or OP diagnosis Normal BMD or no OP diagnosis Patient exit registry Year 2 Normal BMD Or No OP diagnosis Patient exit registry Follow-up visit Subjects were invited for a follow-up visit every 2 years if the prior visit showed low BMD/OP diagnosis Summary of the Registry High level summary 9,312 subjects were enrolled in the registry, 38.5% (3,587) were diagnosed with OP and 43.3% (4,031) with osteopenia at enrollment (Table 1) CharacteristicsTypePatient CountPercentage Patient At enrollment9, % 2 visits4, % > 2 visits1, % BMD At enrollment9, % 2 measurements2, % > 2 measurements1, % EQ-5D* With measurement**3, % At enrollment1, % No measurement6, % OP treatment at enrollment Currently treated1, % Previously treated8459.1% Both8759.4% Neither5, % Diagnosis at enrollment Normal BMD1, % Osteopenia4, % Osteoporosis3, % Other***60.1% Fracture (after age 40) at enrollment No7, % Yes2, % * Only those with complete response to all EQ-5D questions ** EQ-5D started on 2004, therefore the first measurement was not necessary recorded at enrollment *** Including “Fibrous dysplasia”, “Skeletal fluorosis”, “other bone disorder” Table 1. High level summary counts of the registry Patient characteristics at enrollment 91% were female, with average age of 64.1 [SD=11.8] years. Average weight and height were 66.1 [SD=20.6] kg and [SD=22.3] cm, respectively. (Table 2) 23% of patients reported prior history of fracture after age 40, 35% had family history of fractures, 28% had back pain, and 33% were currently smokers. (Table 2) From the first DXA scan at enrollment, 36% (3,292) patients had a T-score (either hip or lumbar spine) ≤ -2.5 and 42% (3,897) between -1 and (Table 2) Among 2,101 diagnosed with OP at enrollment and having ≥1 follow-up visit, 55% (1,146) received bisphosphonates (BIS) (alendronate, optinate, and etidronate), 12% (259) received non-BIS (raloxifene and teriparatide), 79% (1,651) received calcium+vitamin D, and 26% (542) received estrogen. EQ-5D was available for 1,570 patients whose first visit was post The average scores were as follow: mobility: 1.37 [SD=0.49], self-care: 1.11 [SD=0.35], usual activities: 1.34 [SD=0.56], pain/discomfort: 1.91 [SD=0.60], and anxiety/depression: 1.52 [SD=0.57]. (Table 3) Table 2. Patient characteristics at enrollment Conclusion The Swedish patient registry presents opportunities to understand various unmet needs among OP patients as a result of extensive information collected overtime. Examples of analyses include: o Estimation of patients remained at “high risk” of fracture despite benefit of prior treatment o Analysis of Quality of life of OP patients o Analysis of under-treatment and reasons for non-adherence Application of Swedish Registry: N%N responded Patient characteristics Female8,48191%9,312 Age (mean, std) ,312 Weight [kg] (mean, std) ,970 Height [cm] (mean, std) ,965 Current smoker3,04233%9,312 Fractures after age>402,14123%9,312 Family history of fractures1,29014%9,312 Suffered daily back pain2,63228%9,312 T-score Total hip 9, < T-score < -14,20046% T-score≤ -2.51,66118% Lumbar spine 9, < T-score < -13,46038% T-score≤ -2.52,72430% Total hip or lumbar spine 9, < T-score < -13,89742% T-score≤ -2.53,29236% Table 3. EQ-5D (N=1,570) EQ-5Dmeanstd Mobility Answered: I have no problems (N, %)1,065 Self-care Answered: I have no problems (N, %)1,521 Activities Answered: I have no problems (N, %)1,189 Pain/Discomfort Answered: I have no pain (N, %)381 Anxiety/Depression Answered: I have not anxious or depressed (N, %)866 Objective To examine the proportion/characteristics of osteoporotic patients remaining at a high risk despite being treated for ≥ 2 years. “High risk” was defined as: Patients with deteriorating/worsen BMD, defined as T-score decrease ≥ 3% at either hip or spine Patients remaining osteoporotic, defined as T-score ≤ -2.5 at either hip or spine Patients experienced fracture after baseline visit Baseline (Visit 1) 2 nd visit (Visit 2) Step 1: (Patient Selection) Osteoporotic (BMD ≤-2.5), and Treatment naïve Treatment ≥ 2 years Step 3: (Outcome measures) % with deteriorating/worsen BMD % remaining osteoporotic % with fracture Step 2: (Determine treatment duration) Patient reported how long they have been treated since last visit Study diagram Results All (trmt ≥ 2 years) Remained osteoporotic Worsen BMD N%N%N% N Worsen BMD9023.0%8127.3% % Remained osteoporotic % %8190.0% T-score baseline Hip Spine T-score post baseline Hip Spine T-score change Hip Spine Length between visits (year) All (trmt ≥ 2 years) Remained osteoporotic Worsen BMD N%N%N% N Fracture Between baseline and 2nd visit 235.9%103.4%44.4% Patients with 3 or more visits Fractures after the 2nd visit 510.4%411.1%216.7% Treatment received BIS % %4347.8% Fosamax7519.1%5418.2%910.0% Fosamax %6923.2%77.8% Optinate4311.0%3311.1%910.0% Optinate septimum379.4%279.1%77.8% Didronate5213.3%4314.5%1415.6% Non_BIS/Evista9524.2%8629.0%4853.3% Study Design This is a descriptive study using Swedish patient registry data, the inclusion criteria were: Osteoporotic at baseline (BMD≤ -2.5, either hip or spine) Treatment naïve at baseline Returned for a 2nd visit for BMD measurements Proportion and Characteristics of Patients Remaining at “High Risk” Despite Benefit from Prior Treatment Conclusion Using the Swedish Registry data, we found a large proportion of patients remained osteoporotic, and were at a high risk of developing fractures despite being treated for ≥ 2 years. 75.8% (297/392) patients remained osteoporotic, 23.0% (90/392) patients had worsen BMD, 5.9% (23/392) patients experienced fracture prior to their second visit. Table 4. Proportion of patients remaining osteoporotic and with worsen BMD Table 5. Fracture and treatment received Responses to each of the 5 EQ-5D questions 1 = No Problem, 2 = Some Problem, 3 = Extreme Problem or Not Able to Perform